IP Library Granted Patent US 8,313,745
Granted Patent B2
US 8,313,745 · App. 12/796,244 · Granted Nov 20, 2012

Compositions against cancer antigen LIV-1 and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,313,745
App. No.
12/796,244
Granted
Nov 20, 2012
Kind
B2
Abstract

Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Claims (6)

1. A method of treating breast cancer, comprising administering an effective dose of an antibody that specifically binds to LIV-1 polypeptide to a patient diagnosed as having LIV-1 + breast cancer, wherein the antibody is conjugated to a therapeutic moiety, and wherein the LIV-1 polypeptide comprises the amino acid sequence shown in SEQ ID NO:19.

2. The method of claim 1 , wherein the antibody is a monoclonal antibody.

3. The method of claim 1 , wherein the antibody is an antibody fragment.

4. The method of claim 1 , wherein the antibody is a humanized antibody.

5. The method of claim 1 , wherein the therapeutic moiety is a cytotoxic agent.

6. The method of claim 1 comprising administering the antibody with a pharmaceutically acceptable excipient.

Assignments (2)
CHANGE OF NAME Recorded Feb 18, 2013
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC.
Reel/Frame 029825/0070 →
CHANGE OF NAME Recorded Jun 30, 2011
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP
Reel/Frame 026530/0301 →